The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort.
 
Roy E. Strowd
Consulting or Advisory Role - Alexion Pharmaceuticals; Monteris Medical; Monteris Medical; Novocure
Research Funding - Alpha Omega Alpha; American Board of Psychiatry and Neurology; Jazz Pharmaceuticals; NIH; Southeastern Brain Tumor Foundation
Patents, Royalties, Other Intellectual Property - Elsevier, book royalties; Lecturio, lecture royalties
Other Relationship - American Academy of Neurology (AAN)
 
Macarena Ines De La Fuente
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); Anheart Therapeutics; Genentech (I); Regeneron (I); Rigel; SERVIER
Research Funding - ADC Therapeutics (I); BeiGene (I); Genentech (I)
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - AVEO; Bayer; Lilly; Pfizer; Sanofi
Speakers' Bureau - Bayer; Lilly
Travel, Accommodations, Expenses - Pfizer
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Ke Chen
Employment - Merck
Stock and Other Ownership Interests - Merck
Honoraria - Merck
Travel, Accommodations, Expenses - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yanfang Liu
Employment - Bristol-Myers Squibb; Merck
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Cullinan Oncology; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center